Eli Lilly's market share in India fell to 56% in March from 61% a month earlier, according to data from Pharmarack. Meanwhile, rival Novo Nordisk remained steady at 25%. This comes after the patent on semaglutide, the key ingredient in Novo's GLP-1 drugs, expired, leading to a wave of cheaper Indian generics. The cost of these generics has increased significantly, with the monthly cost starting at 5,660 rupees ($61), compared to around 4,200 rupees for higher-end generics, and some generic versions available for as little as 1,290 rupees per month. Experts predict further erosion for Eli Lilly's more expensive tirzepatide-based brands.